Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepatonic acid
Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
1. An atorvastatin piperazine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKαradiation: 7.8, 9.3, 11.8, 16.1, and 19.7.
2. An atorvastatin piperazine having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKα radiation: 4.4, 7.8, 9.3, 11.8, 13.2, 16.1, 17.7, 19.7, 20.4, 22.2, 22.9, 23.8 and 26.4.